Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China National Medicines's Ending Cash Position for the quarter that ended in Jun. 2026 was ¥6,141 Mil.
China National Medicines's quarterly Ending Cash Position
declined
from Dec. 2025 (¥8,892 Mil) to Mar. 2026 (¥5,209 Mil) but then
increased
from Mar. 2026 (¥5,209 Mil) to Jun. 2026 (¥6,141 Mil).
China National Medicines's annual Ending Cash Position
declined
from Dec. 2023 (¥10,798 Mil) to Dec. 2024 (¥8,291 Mil) but then
increased
from Dec. 2024 (¥8,291 Mil) to Dec. 2025 (¥8,892 Mil).
China National Medicines Ending Cash Position Related Terms
China National Medicines Ending Cash Position Historical Data
* Premium members only.
The historical data trend for China National Medicines's Ending Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China National Medicines Ending Cash Position Chart
China National Medicines Ending Cash Position Calculation
Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.
China National Medicines's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as
What does a Ending Cash Position of ¥6,141 Mil mean?
China National Medicines (SHSE:600511) has a Ending Cash Position of ¥6,141 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on China National Medicines and its competitors.
Is China National Medicines' Ending Cash Position too high?
China National Medicines' current Ending Cash Position is ¥6,141 Mil. Overall, China National Medicines has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China National Medicines' Ending Cash Position compare to MCK and COR?
China National Medicines' Ending Cash Position of ¥6,141 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Medical Distribution company?
A good Ending Cash Position depends on the Medical Distribution industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on China National Medicines and its competitors. China National Medicines's current Ending Cash Position is ¥6,141 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China National Medicines stock overvalued right now?
Based on GuruFocus' analysis, China National Medicines (SHSE:600511) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥32.09, compared to a current price of ¥26.77 — trading 16.6% below its estimated fair value. The current Ending Cash Position is ¥6,141 Mil. China National Medicines' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For China National Medicines (SHSE:600511), the current Ending Cash Position is ¥6,141 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China National Medicines (SHSE:600511) Overvalued in 2026?
Based on GuruFocus' analysis, China National Medicines stock appears to be undervalued.
The current stock price of ¥26.77 is trading 16.6% below its estimated GF Value™ of ¥32.09.
GuruFocus considers China National Medicines to be Modestly Undervalued.
Key valuation signals for SHSE:600511:
Ending Cash Position: ¥6,141 Mil
GF Value™: ¥32.09 vs. price of ¥26.77 (16.6% below fair value)
No single metric tells the full story. See the SHSE:600511 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China National Medicines Corp Ltd focuses on producing special drugs and high-end prescription drugs. Its main goal is to provide customers with professional medical services. The company conducts its operations through two primary segments. The Commercial segment is mainly engaged in the sale of pharmaceuticals. The Others segment focuses on pharmaceutical manufacturing and logistics operations.
90GF Score
Get the complete analysis for SHSE:600511
Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600511 has been successfully added to your 
